Ligand to Report Third Quarter 2019 Results on November 5th
October 22 2019 - 4:01PM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announced today plans to report third quarter 2019 financial
results on November 5, 2019. Ligand’s CEO John Higgins, President
and COO Matt Foehr and Executive Vice President and CFO Matt
Korenberg will host the conference call.
Third Quarter 2019 Earnings Call
What:
Ligand conference call to discuss
financial results and provide general business updates
When:
Tuesday, November 5, 2019
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific
time)
Conference Call:
(833) 591-4752 within the U.S.
(720) 405-1612 outside the U.S.
Conference ID - 6093759
Webcast:
Live conference call webcast and replay
accessible at www.ligand.com
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191022006074/en/
Ligand Pharmaceuticals Incorporated Todd Pettingill
investors@ligand.com (858) 550-7893 @Ligand_LGND
LHA Bruce Voss bvoss@lhai.com (310) 691-7100
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024